Biomarker-driven maintenance therapy in extensive-stage-small cell lung cancer: evaluating the SWOG S1929 clinical trial
Tiffany Johnston, Daniel Breadner, Jacques Raphael · 2026
Read Biomarker-driven maintenance therapy in extensive-stage-small cell lung cancer: evaluating the SWOG S1929 clinical trial by Tiffany Johnston, Daniel Breadner, Jacques Raphael (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266856.txt.
Description
Tiffany Johnston, Daniel Breadner, and Jacques Raphael evaluate in 2026 a trial that matched maintenance therapy to a tumor marker in widespread small cell lung cancer. After initial chemotherapy plus immune therapy, patients often relapse quickly, making the maintenance phase a key window. The SWOG S1929 trial tested adding a PARP-blocking drug for patients whose tumors carried the SLFN11 marker.
In 106 patients, adding the drug modestly delayed cancer growth, while overall survival did not improve. The commentary places that result beside other maintenance trials, including one where a different added drug improved both growth delay and survival. Marker-guided maintenance remains promising, the authors conclude, but gains so far are small and need sharper patient selection.
Catalog record
| CREATOR | Tiffany Johnston, Daniel Breadner, Jacques Raphael |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |